Kornimate/medical-research-clean huggingface dataset:
respiratory drive response in copd patients during exercise with non invasive ventilation (niv).

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: a constant load exercise during 10 minutes will be performed in a group of chronic obstructive pulmonary disease patients, in a basal condition (spontaneous breathing); under noninvasive mask ventilation and with high flow nasal cannula. with the aim of reducing dyspnea, increasing exercise tolerance, and unload respiratory muscles, three exercises will be compared in terms of use of respiratory muscles and neural drive measured with paraesternal electromyography.

exercise in chronic obstructive pulmonary disease is limited by dynamic hyperinflation and respiratory muscle overloadleading to severe dyspnea. during exercise, the increase in neural respiratory drive is notable to match ventilatory demand, correlated with breathlessness. non-invasive ventilation may improve neural respiratory drive uncoupling and exercise tolerance. the aim of this study will be prove if non-invasive ventilation and high flow nasal cannula during exercise reduces neural respiratory drive and improves dyspnea, measured with paraesternal electromyography

Eligibility criteria:
inclusion criteria: * patients with severe copd or cystic fibrosis (with an obstructive pattern and air trapping) on the waiting list for a lung transplant, assessed by the lung transplant unit of the 12 de octubre university hospital. * diagnostic criteria for copd according to the gold and residual volume greater than 120% of theoretical * evidence of developing dynamic air trapping by analyzing flow / volume curves during physical exercise. * patients already adapted to home noninvasive mechanical ventilation (niv) waiting for transplantation. exclusion criteria: * presence of comorbidities that limit the patient's physical effort capacity (uncontrolled ischemic heart disease, severe pulmonary hypertension, neuromuscular disease). * refusal of treatment with niv, or inclusion in the study. * inability to perform the proposed exercise in basal conditions and with ventilation.

Keywords: noninvasive ventilation exercise
a trial assessing the safety and feasibility of respiratory muscle training and exercise training in children and adolescents with persistent asthma

Conditions: Asthma

Summary: the purpose of this study is to assess the safety and tolerability of a 6-week inspiratory muscle training and cardiovascular exercise training program in children and adolescents with asthma. to also determine the efficacy of inspiratory muscle training and exercise in increasing respiratory muscle strength and endurance, and to explore relationships between fitness interventions (inspiratory muscle training and exercise), exercise tolerance, airway closure and dyspnea scores.


Eligibility criteria:
inclusion criteria: * 10-17 years of age * clinician-diagnosed asthma * sedentary activity defined as having not participated in a sports team or formal activity (dance classes, gym membership, active hobby requiring physical activity) in the past 12 months or have a * body mass index (bmi) ≥85th percentile (adjusted for sex and age) * child must have a designated caregiver who expresses a commitment to encourage the participant to attend weekly clinic-based exercise and also complete additional home exercise. exclusion criteria: * previous intubation for asthma, * forced expiratory volume in 1 second (fev1) \< 50% of predicted at enrollment; * any major chronic illness that in the opinion of the pi would interfere with participation in the intervention or completion of the study procedures; * inability to complete baseline measurements in a satisfactory manner according to the judgment of the research coordinator or pi * currently active in sports, vigorous play or planned exercise more than 1 time per week on average over the past month * current pregnancy as determined by urine pregnancy test. * parent/caregiver unable to consent in english

Keywords: asthma
understanding how medication is stored in the home

Conditions: Poisoning

Summary: the goal of this study is to increase safe medication storage practices in homes with young children in order to prevent unintentional childhood poisonings. as a step toward meeting this goal, this study aims to determine if an intervention to promote safe storage to patients who have young children in their home, including provision of a lock box or lock bag along with brief counseling versus brief counseling alone, results in 1) increased locked storage (and overall safe medication storage practices) of high-risk prescription medications in the home; 2) increased safe medication storage practices of other medications in the home; and 3) improved safe medication storage related knowledge and attitudes.


Eligibility criteria:
inclusion criteria: * patient in the buprenorphine clinic, high a1c clinic, or palliative care clinic at nyc health + hospitals/bellevue * patient prescribed at least one high-risk mediation. a high-risk medication defined as a prescription medication that may cause significant toxicity or death with the ingestion of only one pill or a single adult dose. * a child less than six years old is present in the patient's home on average at least 8 hours per week. exclusion criteria: * inability to speak and read english or spanish * no phone number for follow-up or unwilling to do follow-up by phone or in person * prior enrollment * patient was involved in pilot study
early smoking reduction or cessation by means of no nicotine electronic cigarette added to standard counselling.

Conditions: Cancer; Myocardial Infarction

Summary: the aim of this study is the evaluation of early smoking reduction or cessation by means of no nicotine electronic cigarette added to standard counselling.

cigarette smoking is one of the major health problems in the modern world for the impact on morbidity and mortality with devastating effects on cardio-cerebrovascular system and on tumor onset. after years of scientific doubts, today the scientific world agrees to define cigarette smoking not a "vice" but a disease. the aim is to evaluate the effect of no nicotine electronic cigarette use in patients with cancer or myocardial infarction, smoking at least 10 cigarettes per day for at least 10 years, in addition to counselling activity performed by specialised dedicated medical doctors. if patient is eligible for this trial, he will be enrolled in this trial and randomized. randomization will be performed using a web-based procedure. study participants will be randomized to electronic cigarette added to standard counselling or only standard counselling. a calendar will be given to the patient to remember the dates of visits or telephone counselling. after the first visit patient will be followed every ten days for the first two month through outpatient clinic visits and telephone counselling. after the first two months patient will return at institute for a last outpatient clinic visit at sixth month.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of cancer and recently operated at european institute of oncology at milan (italy); * patients with a diagnosis of hematology cancer treated at foundation "san raffaele del monte tabor" at milan; * patient with a recent occurrence of acute myocardial infarction from monzino cardiology centre at milan; * age greater than 18 years; * smokers stable for at least 10 cigarettes per day for at least 10 years. exclusion criteria: * patients with life expectancy less than 6 months; * patients who have undertaken structured attempts to stop smoking over the past 3 months.

Keywords: no nicotine electronic cigarette antismoke intervention
a study of fluconazole in the treatment of cryptococcal meningitis in patients who have not had success with amphotericin b

Conditions: Meningitis, Cryptococcal; HIV Infections

Summary: to evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in patients who have had an unsatisfactory response to or have experienced unacceptable toxicity with amphotericin b.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * immunosuppressant therapy. * antiviral therapy such as zidovudine. * prophylaxis for pneumocystis carinii pneumonia. * aerosolized pentamidine. concurrent treatment: allowed: * radiation therapy for mucocutaneous kaposi's sarcoma. not previously treated for acute cryptococcal meningitis and not eligible for pfizer central research, protocol #159. * patients must have a baseline cerebrospinal fluid (csf) culture-positive for cryptococcus neoformans. * written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian. * each individual patient must be approved by pfizer central research prior to study entry. prior medication: allowed: * immunosuppressant therapy. * antiviral therapy such as zidovudine. * prophylaxis for pneumocystis carinii pneumonia. * aerosolized pentamidine. exclusion criteria co-existing condition: patients with the following are excluded: * evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. * history of allergy to or intolerance of imidazoles or azoles. * moderate or severe liver disease. concurrent treatment: excluded: * lymphocyte replacement. patients with the following are excluded: * evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. * history of allergy to or intolerance of imidazoles or azoles. * moderate or severe liver disease. * satisfactory response to amphotericin b and have received a total amphotericin b dose of 15 mg/kg or more since csf culture documentation of the current episode of acute cryptococcal meningitis. * life expectancy of \< 2 weeks. prior medication: excluded: * coumadin-type anticoagulants. * oral hypoglycemics. * barbiturates. * phenytoin. * immunostimulants. * investigational drugs or approved (licensed) drugs for investigational indications. prior treatment: excluded: * lymphocyte replacement.

Keywords: aids-related opportunistic infections meningitis cryptococcosis fluconazole acquired immunodeficiency syndrome amphotericin b
mechanisms of disease severity in multiple sclerosis: an integrative multimodal study

Conditions: Multiple Sclerosis

Summary: this study will identify a combination of disease severity markers (genetic, immunology, epigenetic, imaging) associated with disease severity and progression in a cohort of patients with multiple sclerosis.

the heterogeneity of multiple sclerosis evolution relies on several pathophysiological mechanisms including neuroinflammation, neurodegeneration and remyelination and repair mechanisms. the study will identify markers of disease severity in a longitudinal cohort of patients with multiple sclerosis who are siblings (both siblings having multiple sclerosis) including: biological markers (genetic, immunological and epigenetic markers, advanced mri markers). an integrative model to predict disease progression will be proposed based on multimodal markers.

Eligibility criteria:
inclusion criteria: * clinically isolated syndrome or multiple sclerosis (2010 mc donald criteria) * sibling having clinically isolated syndrome or multiple sclerosis (2010 mc donald criteria) willing to participate to the study * affiliated to the french social security or equivalent exclusion criteria: * cyclophosphamide, mitoxantrone or methylprednisolone infusion within one month before inclusion * multiple sclerosis relapse within one month before inclusion * concomitant severe or uncontrolled disease
amiodarone to prevent post-operative arrhythmias

Conditions: Atrial Fibrillation

Summary: rapid heart rhythms originating from the upper heart chambers (atrial tachyarrhythmias) are very common after open-heart surgery. the hypothesis of the papabear study is that a brief (13 day) peri-operative course of oral amiodarone therapy would be effective and safe for the prevention of these post-operative atrial tachyarrhythmias.

six hundred and one patients who were about to undergo non-emergent open-heart surgery were randomized to receive oral amiodarone (10 mg/kg/day) or its matching placebo from six days before surgery through 6 days after surgery. the major outcome tracked was the incidence of more than 5 minutes of an atrial tachyarrhythmia that prompted therapy by the sixth post-operative day. safety was assessed by the incidence of dosage reduction of blinded therapy, non-fatal post-operative complications, and in-hospital mortality. the randomization scheme was stratified to permit separate analysis of patients less than versus more than or equal to 65 years of age, patients having coronary artery bypass surgery alone versus those having valve surgery with or without concomitant bypass surgery, and patients also receiving versus not also receiving concomitant therapy with a beta-blocker medication.

Eligibility criteria:
inclusion criteria: * non-emergent coronary artery bypass surgery or valve replacement or repair * informed consent exclusion criteria: * any heart rhythm other than sinus * myocardial infarction within two weeks * class iv congestive heart failure * requirement for antiarrhythmic drug therapy * history of sustained atrial tachyarrhythmias * treatment with amiodarone within 3 months * sinus bradycardia (less than 50 bpm) while awake * advanced conduction system disease * prolonged qt interval * clinical hypo- or hyperthyroidism * women of child bearing potential

Keywords: atrial fibrillation atrial flutter amiodarone post-operative coronary artery bypass surgery valve replacement or repair
to evaluate thrombosis risk in chemotherapy patients with solid tumors who receiving thrombocytopenia treatment

Conditions: Chemotherapy-induced Thrombocytopenia

Summary: chemotherapy-induced thrombocytopenia (cit) is a common hematological toxicity in patients with solid tumors undergo chemotherapy, which can increase the risk of bleeding, prolong hospital stay, increase medical costs, and even lead to death in severe cases. the incidence and severity of cit varies among different chemotherapy regimens. recombinant human interleukin-11 (rhil-11) and recombinant human thrombopoietin (rhtpo) have been approved for the treatment of chemotherapy-induced thrombocytopenia. tumor patients are at high risk for venous thromboembolism (vte). in the clinical study of rhil-11, it was found that the administration of rhil-11 in healthy subjects caused an increase in the plasma concentration of vwf factor in the form of normal mults. the application of rhil-11 in patients with myeloid leukemia can increase the concentration of α2 globulin, fibrinogen and prothrombin time. however, there have been no large-scale clinical studies at home and abroad to evaluate whether platelet raising therapy will increase the risk of thrombosis in chemotherapy patients with solid tumor. this study is aimed to evaluate the efficacy and safety of platelet upwelling therapy in patients with solid tumors undergoing chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with pathological diagnosis of solid tumors or lymphomas. * have received chemotherapy. * diagnosed of cit. * continuous use of platelet raising drugs for at least 5 days. exclusion criteria: * thrombocytopenia caused other than chemotherapy, including but not limited to: traditional chinese medicine, congenital platelet disease, etc. * the basic value of platelet count is continuously higher than 300×10\^9/l. * those without blood routine or coagulation function data. * those who received non-chemotherapy drugs that may cause thrombocytopenia, such as sulfonamides. * pseudothrombocytopenia due to ethylenediamine tetraacetic acid (edta) as an anticoagulant in test samples.
focus group interviews of patients with permanent or temporary enterostomas

Conditions: Patient Perspective; Living With an Enterostoma; Mastery; Empowerment

Summary: the study seeks to gain knowledge about new and of alternative ways of organizing ostomy training based on informants' own experiences of life with a stoma. the study is designed and conducted as qualitative focus group interviews with three different groups of patients with enterostomas (5-8 in each group): a) people with permanent enterostoma due to cancer, 2) people with permanent enterostoma due to non-cancer and 3) people with a temporary ileostomy.

the study is investigating the perspective of the patients who have actually experienced having surgery and living with an enterostoma. by applying this method it is possible to gain access and in depth knowledge of complex issues including sensitive data. the dialogue with peers can lead to experiments and associations which might stimulate the informants to produce new insights within the individual and in the group. the interviews will be transcribed in full and analyzed with qualitative content analysis with a phenomenological and hermeneutical approach

Eligibility criteria:
inclusion criteria: * patients with permanent enterostoma due to cancer. * patients with permanent enterostoma due to other causes. * patients with temporary ileostomy. exclusion criteria: * patients with severe mental disorders. * patients who do not communicate in danish. * patients with severe hearing impairment.

Keywords: quality of life patient education rehabilitation focus group interview
evaluation of an icu hyperglycemia protocol using insulin aspart

Conditions: Hyperglycemia

Summary: in response to the evidence supporting "tight" glucose control (70 - 110) in the critical care setting, the mmh icu developed a protocol utilizing regular intravenous insulin. this protocol was initiated in 2002. monitoring of the data collected revealed effective glycemic control when this protocol was used. however, limited utilization has led to overall ineffective glycemic control in this icu. the poor utilization is largely due to a general reluctance of physicians to start their patients on an intravenous insulin infusion. as contributing to this poor compliance is the "open" nature of the icu. the mmh icu is an "open" icu, meaning that many physicians across multiple subspecialties admit to this unit. approaches to controlling hyperglycemia vary greatly, depending largely upon the treating physician. in an attempt to improve overall glycemic control in this "open" icu, the subcutaneaous insulin aspart hyperglycemia protocol (siap) was developed which incorporates a subcutaneous insulin aspart regimen that triggers the use of a regular insulin infusion protocol when the siap is not adequately controlling the patient's blood glucose. this study aims to evaluate 1) the effect the siap on overall glycemic control in the icu, 2) the effectiveness that the siap has on controlling blood glucose as compared with past practices using regular insulin, and 3) the effect the siap has on patient complications and outcomes in the mmh icu.


Eligibility criteria:
inclusion criteria: valid physician order of the protocol. - exclusion criteria: no valid phycician order for the protocol -
sensory processing in tourette syndrome

Conditions: Tourette Syndrome

Summary: the purpose of this study is to learn more about how patients with tourette syndrome deal with sensory stimuli in their environment such as bright lights, loud noises, physical sensations such as shirt tags, etcetera. we will compare responses of patients with tourette syndrome to those without tourette syndrome. the study aims to better characterize sensory processing abnormalities by sensory modality: the investigators will use a measuring tool based on dunn's 1997 model of sensory processing, the sensory profile, which will allow the investigator to characterize both registration and response to external stimuli, as well as to delineate which sensory modalities are affected. identifying which sensory modalities are most affected may guide future research into the pathophysiology of sensory processing abnormalities in ts. the investigators also aim to correlate sensory processing abnormalities with the presence of obsessive compulsive disorder (ocd), attention-deficit/hyperactivity disorder (adhd) , and autism spectrum disorders.

while it is widely recognized that patients with tic and tourette syndrome (ts) experience heightened sensitivity to or abnormal processing of internal sensations, it has also been suggested that patients with tic and ts experience abnormal processing of external sensations/stimuli. while this sensitivity to external stimuli does not appear to trigger motor or vocal tics, it can significantly affect quality of life. these sensitivities can be a source of irritation, discomfort, and distraction that can be equally or more disruptive than vocal or motor tics. heightened sensitivity to external stimuli or other abnormalities of external sensory processing have been identified in other neuropsychological disorders such as autism spectrum disorders, schizophrenia, traumatic brain injury, adhd, and obsessive-compulsive disorder (ocd) . ts often presents with co-morbid diagnoses including attention-deficit and hyperactivity disorder (adhd) and obsessive-compulsive disorder (ocd) but it is not currently known whether sensitivity to external stimuli is due to a central processing abnormality common to these disorders. this study's objective is to use a variety of questionnaires to determine how external stimuli along with the presence of other disorders effect sensory processing.

Eligibility criteria:
inclusion criteria: * targeted study population includes patients diagnosed with tourette syndrome * patient of university of florida movement disorders center diagnosed with tourette syndrome by a movement disorder specialist, according to dsm iv diagnostic criteria * age 6-18 * presence of parent or guardian able to provide consent in the case of minors exclusion criteria: * inability of patient or, in the case of minors, parent/guardian to provide informed consent * inability of designated person to complete questionnaires. in the case of patients' age 10 and younger, this would refer to the parent/guardian. in the case of patients older than 10, this could be either the patient or their parent/guardian

Keywords: tourette syndrome tics
pulmonary arterial hypertension quality enhancement research initiative extension program

Conditions: Pulmonary Arterial Hypertension

Summary: knowledge translation program for the guidelines and evidence-based management of pah patients

to improve the management of pah patients through an evidence-based approach aimed at achieving optimal who functional class (defined as: 1) improvement of fc iii or iv to fc ii; 2) improvement of fc ii to fc i; or 3) maintaining fc ii or i)

Eligibility criteria:
inclusion criteria: 1. male and female adults (≥ 18 years of age) 2. documented diagnosis of pah (all of the following): i. rhc demonstrating mpap \> 25 mm hg and pcwp ≤ 15 and pvr \> 3 ii. fev 1 \> 50% predicted normal iii. v/q and/or ct scan excluding the thromboembolic etiology 3. diagnosis of pah \< 3 years 4. need for pah specific treatment 5. desire to participate and signs an informed consent exclusion criteria: any of the criteria below: 1. poor mental function, drug or substance (e.g.,alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study 2. prior participation in this program 3. patients with pulmonary hypertension classified as group 2 - 5 updated clinical classification of pulmonary hypertension (5th world symposium on ph modified classification of ph)